1 / 44

Breast Conference 2/15/2012

Breast Conference 2/15/2012. RN. 39 Asian/Pacific Islander presenting with a right breast mass and swelling 1-2 month duration Pain in the area. RN. Menarche: 18y G1P1 (33y), breastfeeding: 6m OCP: none HRT: none Premenopausal (LMP 12/2011) Hx breast bx : none Hx breast Ca: none

ownah
Download Presentation

Breast Conference 2/15/2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breast Conference 2/15/2012

  2. RN • 39 Asian/Pacific Islander presenting with a right breast mass and swelling • 1-2 month duration • Pain in the area

  3. RN Menarche: 18y G1P1 (33y), breastfeeding: 6m OCP: none HRT: none Premenopausal (LMP 12/2011) Hx breast bx: none Hx breast Ca: none Fhx: none Shx: caffeine(+), soy(-), tobacco(-), ETOH(-) Bra: 38C

  4. RN PMH: none PSH: c/s Meds: multivitamins Allergies: Percocet

  5. RN PE: Right breast: Large, hard mass involving 4 quadrants, minimal nipple retraction. Thickening of the skin and peaud’orange Left breast: Within normal limits Right axilla: Enlarged lymph node, relatively immobile No left axillary, supraclavicular or cervical adenopathy

  6. RN • Pregnancy test – positive • OB-GYN: • Missed abortion?

  7. RN Radiology: Diagnostic mammogram: Right – 21 o’clock anterior depth density. Skin thickening and nipple retraction. Right posterior superior breast – multiple enlarged nodes US: Right – 5.2*2.8*5.7cm irregular mass central to the nipple anterior depth, associated with skin thickening Right axilla – multiple enlarged nodes with no fatty hilum

  8. RN Radiology: MRI: PET/CT:

  9. RN Pathology: Right breast lesion: Infiltrating ductal carcinoma with mucinous features Grade 2 ER(98%) PR(61%), HER2(+2, FISH pending) Right axillary lesion: Mucinous carcinoma No lymph tissue seen

  10. RN • 39 F, right breast inflammatory carcinoma stage IIIB, cT4dN2Mx • FISH pending

  11. RN

  12. RN • Surgery – • Mediport • Medical oncology – • Neoadjuvant chemotherapy • Radiation oncology – • Plastic surgery – • Genetics – • Psychosocial –

  13. 35 F, pregnancy 13w • inflammatory breast carcinoma, bulky axillaryadenopathy • Grade 3, ER/PR+, HER2- • Chest MRI, liver US – negative • Neoadjuvant chemotherapy – FAC (5FU, doxorubicin, cyclophosphamide) • Minimal response only, tx changed to Docetaxel (week 25) • Healthy newborn (week 39)

  14. sf • Clinical exam, US, MRI – complete response • MRM – no residual breast tumor, 5/16 nodes • Goserelin and Tamoxifen • Radiation

  15. Pregnancy related breast cancer: • Diagnosed during pregnancy or within a year after delivery • History and Physical examination • Genetic and environmental risk factors are similar to those for the age adjusted population • No increased risk for BRCA mutation carriers during pregnancy • Patients are young, refer to genetic counseling • Physiological breast changes can obscure masses, and the patients tend to be diagnosed at a later stage • 80% of breast lesions during pregnancy are benign

  16. Diagnosis • Gestational changes might alter the tissue structure • US – • First tool for diagnosis • Mammogram – • To rule out bilateral and multicentric disease • MRI • Should only be used when would change treatment • No well designed studies of efficacy and safety of breast MRI in pregnancy • Gadolinium may pass through the placenta, potential toxic effects are unknown • Other approved contrast agents can be used • Core biopsy – • Safe • Sensitivity around 90% • Rare milk fistulas • FNA not recommended • Notify pathologist of pregnancy

  17. More women are delaying childbirth • More diagnosis during pregnancy • More women choosing not to terminate the pregnancy • Incidence in California Obstetrics Registry: 13:100,000 live births • Swedish study: 37.4:100,00 (pregnancy associated breast cancer)

  18. Diagnosis and staging: • Imaging: • Mammogram – with proper fetal shielding lower sensitivity during pregnancy • US – high rates of mass identification in pregnancy • MRI – animal models showed Gadolinium to cross the placenta, and is associated with fetal abnormalities scant data on the use of Gadolinium for non breast MRI in pregnancy

  19. Diagnosis and staging: • Biopsy – case report of milk fistula with core needle biopsy (other reports showed no complications) mention to the pathologist that the patient is pregnant • Staging evaluations – • Echo – prior to anthracyclines • Stage ≥II: • Liver ultrasound • MRI without contrast of the spine • Chest x-ray with fetal shielding • CT, bone scans – not recommended routinely • Evaluation of the fetus before initiation of therapy

  20. Surgery – • Similar risk of fetal abnormalities as pregnant patients without surgery • Both mastectomy and breast conservation surgery are feasible with minimal post-op complications • SLN biopsy: • Estimated radiation to fetus is low • Concern regarding the use of isosulfan blue dye – unknown fetal effect • More safety data needed • Radiation – • Should be delayed until after delivery

  21. Chemotherapy – • Same indications as in a non-pregnant patients • Most are rated pregnancy category D • 14-19% fetal malformations when given in first trimester • 1.3% fetal malformations in second and third trimester • Anthracyclines – • Multiple case series, … • Taxanes – • Several studies, often delayed until after delivery • Concerns of effectiveness d/t up-regulation of P-450 during pregnancy

  22. Biological agents • Trastuzumab – oligo and anhydramnios should be delayed • Lapatinib – 1 case report (women conceived while on drug, with a healthy newborn) not recommended – lack of information • Endocrine therapy • Tamoxifen – associated with birth defects

  23. Prognosis • Delays in diagnosis and treatment may influence outcomes • Recent studies did not show pregnancy associated breast cancer to be an adverse prognostic sign

  24. Less recommendations for termination of pregnancy • Chemotherapy during pregnancy decreased milk production • Secreted in breast milk and contraindicated in lactating patients Conclusion – Treatment with multidisciplinary approach, communication with obstetrician There should be minimal delay in therapy No significant long term concerns identified in children exposed to chemotherapy in utero

  25. LT • 58 AAF presenting with a palpable mass and an abnormal mammogram

  26. LT Menarche: 9y G4P2 (20y), breastfeeding: none OCP: 10y HRT: none Postmenopausal (41y) Hx breast bx: none Hx breast Ca: none Fhx: Breast cancer – maternal aunt (60y) Colon cancer - maternal aunt (61y) Unknown cancer – paternal uncle Shx: caffeine(3cups/d), soy(-), tobacco(recent smoker: 15 pack years), ETOH(occasionally) Bra: 38D

  27. LT PMH: HLD, anemia, seizure (childhood) PSH: cholecystectomy, c/s*2 Meds: Lisinopril, Vytorin, Chantix Allergies: Ibuprofen, Penicillin

  28. LT PE: Right breast: 1.5cm hard mass, 12 o’clock 10cm from nipple Left breast: Within normal limits No axillary, supraclavicular or cervical adenopathy

  29. LT Radiology: Diagnostic mammogram: Right – lobulated mass 12 o’clock, far superior position US: Right – solid irregular mass, 1.4*1.5*1.7cm, 1 o’clock 10cm from nipple Right axilla – no suspicious findings

  30. LT Pathology: Right breast lesion: Infiltrating ductal carcinoma Grade 2 ER(100%) PR(100%), HER2(-)

  31. LT • 58 F, IDC stage IA cT1cN0M0

  32. LT

  33. LT • Surgery – • Medical oncology – • Radiation oncology – • Plastic surgery – • Genetics – • Psychosocial –

More Related